Oncobiologics (OTLK)
(Delayed Data from NSDQ)
$7.90 USD
+0.04 (0.51%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $7.89 -0.01 (-0.13%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 8/12/24 |
---|---|
Current Quarter | -1.06 |
EPS Last Quarter | -1.55 |
Last EPS Surprise | -76.14% |
ABR | 1.14 |
Earnings ESP
|
0.00% |
---|---|
Current Year | -4.08 |
Next Year | -2.45 |
EPS (TTM) | -4.95 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (9/2024) |
Next Year (9/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | NA | 1.43M | NA | 9.63M |
# of Estimates | NA | 1 | NA | 4 |
High Estimate | NA | 1.43M | NA | 15.37M |
Low Estimate | NA | 1.43M | NA | 3.80M |
Year ago Sales | 0.00M | 0.00M | NA | NA |
Year over Year Growth Est. | NA | NA | NA | NA |
Earnings Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (9/2024) |
Next Year (9/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -1.06 | -0.86 | -4.08 | -2.45 |
# of Estimates | 3 | 3 | 2 | 4 |
Most Recent Consensus | -0.93 | -1.01 | -4.26 | -3.22 |
High Estimate | -0.81 | -0.78 | -3.89 | -2.05 |
Low Estimate | -1.43 | -1.01 | -4.26 | -3.22 |
Year ago EPS | -1.60 | -1.00 | -4.80 | -4.08 |
Year over Year Growth Est. | 33.75% | 14.00% | 15.00% | 39.95% |
Agreement - Estimate Revisions
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (9/2024) |
Next Year (9/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 0 | 0 | 0 | 0 |
Up Last 60 Days | 2 | 1 | 0 | 0 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 0 | 0 | 0 | 0 |
Down Last 60 Days | 1 | 2 | 2 | 2 |
Magnitude - Consensus Estimate Trend
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (9/2024) |
Next Year (9/2025) |
|
---|---|---|---|---|
Current | -1.06 | -0.86 | -4.08 | -2.45 |
7 Days Ago | -1.06 | -0.86 | -4.08 | -2.45 |
30 Days Ago | -1.06 | -0.86 | -4.08 | -2.45 |
60 Days Ago | -0.86 | -0.71 | -3.60 | -1.84 |
90 Days Ago | -0.86 | -0.71 | -3.60 | -1.84 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (9/2024) |
Next Year (9/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -1.06 | -0.86 | -4.08 | -2.45 |
Zacks Consensus Estimate | -1.06 | -0.86 | -4.08 | -2.45 |
Earnings ESP | 0.00% | 0.00% | 0.00% | 0.00% |
Surprise - Reported Earnings History
Quarter Ending (3/2024) |
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -1.55 | -0.80 | -1.00 | -1.60 | NA |
Estimate | -0.88 | -1.00 | -1.00 | -0.80 | NA |
Difference | -0.67 | 0.20 | 0.00 | -0.80 | -0.32 |
Surprise | -76.14% | 20.00% | 0.00% | -100.00% | -39.04% |
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more